Replies to post #1966 on Insmed Inc (INSM)

[jellybean]

Exactly. This has nothing to do with the sales of their medicines. All insurors or payors contract with the drug vendors for the cost of the medicines. It is unheard of for a drug company to publicize the price of another companies drugs. And, the table is most likely not accurate. Insmed stated what the price was for treatment of a child of a given weight (23 kg) and a set dosing (2 mg/kg). Tercica took that number extrapolated the cost of the vial and then developed their table. My guess is that Insmed has priced the medicine according to the weight of the child and so the children are not charged for "unused portion" of the vial.

I have also noticed from reading the FDA documents that the iplex commercial lot is of better quality than the clinical supply. That probably means that the drug is more stable and as long term data rolls out do not be surprised to see that the vial could be reused for a second dosing.

Tercica may have just opened themselves up for a lawsuit which makes me wonder if that isn't part of their plan. Are they baiting Insmed to force yet another feckless lawsuit down Insmed's throat?

[theonlyslacker]

Thanks, as usual, for the education Bob. Learned a lot from you over the years.

TRCA can take down the Kingsbridge funds at will for an average of the past 8 days PPS or $3.00 whichever is greater. Correct? Therefore wouldn't it seem reasonable that unless you really got a large bounce from this PR it would have limited impact since the stock price has fallen pretty badly over the past couple of weeks?

Second, wouldn't any investor/banker in their right mind look at the steep decline in share price (granted it could be the result of anticipated dilution) and the meager quarterly results even considering first to market position and flinch at buying this at or near this current price? Therefore with the intention of an offering, this line of reasoning would continue to drive share prices lower. Right?

Finally, realistically in order to afford this treatment, a family would either have to have insurance or be fairly well off to afford either of these options. So competing on price seems to be a weak market tactic.

We will see the impact of the PR early today on the SP. Quite possible I am overthinking this thing but it seems reasonable whatever TRCA is trying to do they need more than the $75M available from Kingsbridge. Looking forward to the education. Slacker